Drug Response Prediction on GDSC2 (10-fold drug-blind CV, leave-one-drug-out CV)
0.772All-drug Correlation (r)Mechanism-stratified training
Evaluation Results
| Method | Links | |||
|---|---|---|---|---|
| Mechanism-stratified trainingMoA class=Mitosis, n=7, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.772 | 0.713 | 0.788 | |
| Mechanism-stratified trainingMoA class=Genome integrity, n=13, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.742 | 0.57 | 0.73 | |
| Mechanism-stratified trainingMoA class=PI3K/MTOR signaling, n=23, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.61 | 0.489 | 0.702 | |
| Mechanism-stratified trainingMoA class=RTK signaling, n=12, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.605 | 0.454 | 0.64 | |
| Mechanism-stratified trainingMoA class=Apoptosis regulation, n=13, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.524 | 0.331 | 0.515 | |
| Mechanism-stratified trainingMoA class=ERK MAPK signaling, n=11, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.427 | 0.565 | 0.723 | |
| Mechanism-stratified trainingMoA class=EGFR signaling, n=7, Backbone=Ridge regression, Features=RNA PCA-550 + mutation PCA-2002026.05 | 0.425 | 0.697 | 0.799 |